| Sumario: | The high heterogeneity and resistance of glioma present significant challenges in clinical treatment. The rapid development of multi-omics technologies has greatly advanced the understanding of the molecular mechanisms, resistance characteristics, and potential new drug targets in glioma. Building on this, multi - omics data is now being used for drug screening, mechanism exploration, and clinical trial guidance, thereby accelerating the translation of novel therapies and precision medicine strategies into clinical applications for the treatment of glioma. This review focuses on the latest advancements in the application of multi-omics technologies in glioma drug research and development, highlighting how insights into genetic mutations, gene expression, protein functions, and metabolic reprogramming can aid in understanding the molecular mechanisms, resistance, and complexity of the tumor microenvironment. Furthermore, it provides critical support for the identification of new drug targets, the development of personalized treatment plans, and drug screening, thus advancing the field of personalized and precision medicine in the treatment of glioma.
|
|---|